Fewer than one in ten people who could benefit from weight loss jabs can access them due to high costs and supply issues associated with the medication, the World Health Organisation (WHO) has warned.
There are more than a billion people worldwide living with obesity and WHO has called for fairer access to GLP-1 medication such as Wegovy, in its first guidance on the drugs.
